AMAG Pharma (AMAG) Posts Wider Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMAG Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update
August 7, 2019 7:01 AM EDTPromoted products achieved sequential and year-over-year revenue and market share growth
2019 financial guidance lowered: exiting Makena intramuscular market and removing milestone revenue
Vyleesi on-track for national launch in September
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the second quarter ended June 30, 2019 and provided a business update.
We are pleased to report both year-over-year and sequential revenue and market share growth in... More
